| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.026 | 0.4 |
| mRNA | bid1870 | gCSI | pan-cancer | AAC | 0.045 | 0.4 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.044 | 0.4 |
| mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.094 | 0.4 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | 0.026 | 0.4 |
| mRNA | 17-AAG | FIMM | pan-cancer | AAC | 0.14 | 0.4 |
| mRNA | DBeQ | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | AZD6244 | UHNBreast | pan-cancer | AAC | -0.25 | 0.4 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.046 | 0.4 |